OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
7
Results
Show all
Save search
Copy query
Show results for
Unknown
(6)
Proteomics
(1)
Organisms
Chlorocebus sabaeus
(1)
Repository
pride
(1)
Tissue
Fibroblast
(1)
Kidney
(1)
Disease
Hyperekplexia
(1)
Technology Type
Bottom-up proteomics
(1)
Data-dependent acquisition
(1)
Mass Spectrometry
(1)
Publication Date
2025
(1)
Release Date
2021
(2)
2026
(1)
2025
(1)
2023
(1)
2022
(1)
Lab affiliation
Laboratorio de Proteómica Cardiovascular Centro Nacional de Investigaciones Cardiovasculares
(1)
Previous
page
1 / 1
You're on page
1
Next
page
Sort
by:
Relevance
Page size
10
COS7 GlyT2 variants associated with hyperekplexia
Multiplexed LC-MS/MS analysis of heterologous cells expressing a new GlyT2 variant found in an infantile patient diagnosed with hyperekplexia.
ORGANISM(S):
Chlorocebus sabaeus
2025-08-04
|
PXD061845
|
Pride
Co7 cells
Glyt2 variants
Cite
A New GlyT2 Variant Associated with Hyperekplexia
Not available
S-EPMC12295724
|
biostudies-literature
Cite
Underutilization and Quality Gaps in Blood Culture Processing in Public Hospitals of Peru.
Not available
S-EPMC8832895
|
biostudies-literature
Cite
Prevalence of Antimicrobial Resistance in Gram-Negative Bacteria Bloodstream Infections in Peru and Associated Outcomes: VIRAPERU Study.
Not available
S-EPMC10622474
|
biostudies-literature
Cite
Safety and efficacy of 6% hydroxyethyl starch in patients undergoing major surgery: The randomised controlled PHOENICS trial.
Not available
S-EPMC12700675
|
biostudies-literature
Cite
Timing of surgery following SARS-CoV-2 infection: an international prospective cohort study.
Not available
S-EPMC8206995
|
biostudies-literature
Cite
SARS-CoV-2 infection and venous thromboembolism after surgery: an international prospective cohort study.
Not available
S-EPMC8652887
|
biostudies-literature
Cite
Previous
page
1 / 1
You're on page
1
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets